StreptAvax (ID Biomedical).
ID Biomedical, under license from the University of Tennessee, is developing StreptAvax, a potential subunit vaccine against group A streptococcal infection. By January 2005, analysis of data from phase II clinical trials conducted in adults was completed. Pediatric trials are not expected to begin before 2007.
McMillan
David
D
The Queensland Institute of Medical Research, Bacterial Pathogenesis Laboratory, Brisbane, Australia. David.McMillan@qimr.edu.au
D000293:Adolescent; D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007115:Immunization Schedule; D007273:Injections, Intramuscular; D008875:Middle Aged; D012703:Serotyping; D013290:Streptococcal Infections / Q000517:prevention & control*; D022541:Streptococcal Vaccines / Q000008:administration & dosage*; D013297:Streptococcus pyogenes / Q000145:classification / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage
D000907:Antibodies, Bacterial; D022541:Streptococcal Vaccines; D014614:Vaccines, Synthetic; C488512:hexavalent group A streptococcal vaccine